Across healthcare systems worldwide, the work of neurologists reflects both scientific precision and adaptive problem-solving. As neurological conditions grow more complex, their responsibilities increasingly blend clinical judgment with emerging technologies. In well-resourced settings, they lead interventions that integrate high-field MRI, immunotherapies, and neural interface technologies. These innovations support faster diagnoses, targeted treatments, and neuroplastic recovery following injury. Meanwhile, in under-resourced areas, neurologists often rely on clinical acumen and creative diagnostics to manage seizures, neuropathies, and neuroinfectious diseases with limited tools. Their adaptability often dictates whether patients gain access to stabilizing care or face long-term disability. This professional contrast underscores a shared goal—restoring function and dignity to patients living with neurological disorders. Despite these differences, all neurologists face growing complexities related to aging populations, comorbid psychiatric symptoms, and emerging environmental neurotoxins. These challenges require long-term engagement beyond episodic care. They are not only caregivers but educators, mentors, and system-level advocates for better neurology infrastructure. Advocacy efforts often include rural outreach programs, policy reform, and medical education expansion. With the rise of neurogenetics and precision diagnostics, neurologists are also reconfiguring treatment paradigms—moving beyond symptom control toward disease modification. Their work is deeply interdisciplinary, bridging physiology, cognition, and data science. Whether in metropolitan hospitals or rural clinics, neurologists serve as keystones in the evolving architecture of global neuroscience care.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States